|
Creativity and the never-ending search for knowledge
will always be the basis on which our human civilization is anchoring
its hopes for a better world. In particular, creativity is a unique
and delicate process, which requires substantial encouragement and
support. Dr Dario Kriz, CEO and founder of the company, has a background
as a scientist and an inventor witch has encouraged him to build
up a structure that enables others to realize their creative ideas.
The Institute has resources to conduct research and development
at a professional level within applied biotechnology and medical
technology. Since its foundation in 1990 several unique patented
methods have been invented at the Institute.
The European Institute of Science is currently listed
on the SBI stock exchange in Stockholm. A total of 3 million shares
are distributed among more than 500 shareholders.
The shareholders are individually offered to enter into
new projects jointly with the Institute. Currently, the Institute
and its shareholders posses shares in the following companies: CHEMEL
Inc., IMPLEMENTA HEBE Inc., GENOVIS Inc. and LIFEASSAYS Inc. The
strategy of the Institute is to expand its company portfolio and
to commercialize advanced scientific niche products for worldwide
research.
The magneto immunotherapy project
A research project called magneto immunotherapy is ongoing
at the Institute. The long-term goal is to develop new types of
pharmaceuticals and instrumentation for alternative treatment of
diseases such as cancer or infections. Specially designed magnetic
particles are selectively targeting cells or invading bacteria,
and a subsequent destruction is achieved using an external alternating
magnetic field. In contrast to conventional therapy, the immune
defense and well being of the patient is not expected to be affected.
Two patent applications have been filed focusing on the therapeutically
active magnetic particles and construction of the magnetic field
generator.
What makes the European Institute of Science a unique
center of excellence is its competence in research, international
networking and its laboratory/prototype workshop facilities. This
enables new ideas to be rapidly developed and evaluated. Some current
projects and products are listed below.
New synthetic antibodies
Development of various synthetic biomolecules, which
have a commercial use, using techniques such as molecular imprinting
and phage display libraries is ongoing.
External projects in our labs
We are continuously contacted by researchers that would
like to develop projects in our laboratories. Unfortunately, such
projects must be kept confidential.
Magnetic Permeability Products
The Institute has developed and manufactures instruments
and paramagnetic fluids for research and laboratory use. A magnetic
permeability meter, MPM 100, will be made commercially available
during spring 2001. The instrument can determine the magnetic permeability
of any substance by measuring the inductance change of an internal
coil. Some of the paramagnetic fluids have been already offered
for sale since winter 2000.
The Institute provides incubation facilities and support
services for researchers and small companies that possess promising
ideas.
The strategy is to enter into the projects at a early
stage while the projects are still in their conceptual phase. In
return the researcher has access to research facilities and the
competence available within the Institute. The final commercial
exploitation is performed in separate spin-off companies with the
researcher and entrepreneur-to-be as the majority owner and with
the focus on the introduction of the company to the stock exchange.
The Institute offers
- Its competence in research
- Laboratory facilities
- Prototype/workshop facilities
- Economical and legal advice
- Assistance with patent and trademark applications
- Seed capital
The Institute has part ownership or options for shares
in the following companies. The shareholders of the European Institute
of Science have the possibility to invest directly in a specific
company.
Chemel Inc.
Chemel Inc. was founded in 1997 as a spin-off company
from the European Institute of Science. The Institute owns 7% of
the company, via shares (0,4%) and options (6,6%).
Business idea
Chemel is developing, marketing and selling the patented
electrochemical analytical instrument, the SIRE® Biosensor, to the
pharmaceutical, food & beverage and forest industry, globally.
Chemel will develop software and new applications (in
vivo needle sensors) within the SIRE® Biosensor concept.
Technology and patents
The operational principle of the SIRE® Biosensor is
based on the use of special enzyme reagents. During each measurement
a small aliquot of enzyme is transported to the end of the sensor
probe (reaction chamber) where it reacts with the analyte and yields
an electrical signal that accurately correlates to the concentration
of the analyte.
Patents have been granted in the US and Sweden.
Market
Chemel has signed a global distribution and cooperation
agreement with Diffchamb Inc. concerning the SIRE® Biosensor. The
world market for this kind of chemical analyses for the food &
beverage industry alone is estimated to a value of 60 million US$.
Diffchamb and Chemel expect to take a market share of approximately
20% within 3-5 years.
|
Company name:
|
Chemel AB (priv)
|
|
Year of incorporation:
|
1997
|
|
Shares (total):
|
233 300
|
|
Shares (Institute):
|
1000 + 15330 (options)
|
Genovis
Genovis was founded in 1999 by Dr. Sarah Fredriksson
in co-operation with the European Institute of Science. The Institute
has contributed with financial and technical support. European Institute
of Science owns 20,7% of the company.
Business idea
The business idea is to develop, manufacture and market
the MagnetoPore™ technology, which will provide scientists worldwide
with a new reliable tool for the transportation of molecules in
and out of living cells.
Technology and patents
The technology comprises special magnetic reagents,
which attach to cell surfaces and create pores when exposed to magnetic
fields. Presently a prototype has been developed and a worldwide
patent application has been filed.
Market
The market for molecular biology correspond to 38 %
of the total market for biochemical research reagents, which is
estimated to reach a value of 3.3 billion US$ in Europe during 2003,
according to Frost and Sullivan in European Biochemical Research
Reagent Markets (#3323-53). The MagnetoPore™ technology will be
marketed as a kit and is initially expected to reach 1 % of the
total market with a future potential of 3-5 %. This 1 % of the market
for molecular biology reagents corresponds to approximately 12 million
US$ in Europe.
Genovis was founded in 1999 by Dr. Sarah Fredriksson
in co-operation with the European Institute of Science. The Institute
has contributed with financial and technical support. European Institute
of Science owns 20,7% of the company.
|
Company name:
|
Genovis AB (priv)
|
|
Year of incorporation:
|
1999
|
|
Shares (total):
|
1 256 000
|
|
Shares (Institute):
|
260 000
|
Implementa Hebe
Implementa Hebe was founded in February 2000 as a spin-off
company from the European Institute of Science. The Institute owns
34,3% of the company and is entitled to an annual royalty of 5%.
Business idea
The business idea of Implementa Hebe isto produce, market
and sell CoolHeater™, a patented magnetic stirrer.
Technology and Patents
Implementa Hebe has developed a magnetic stirrer that
can both cool and heat liquids during stirring.
Three prototypes were developed and evaluated during
2000. The production of a test series consisting of 20-30 instruments
is in progress and will be used for test marketing. The final commercial
exploitation will take place in 2002.
A patent has been granted in Sweden.
Market
The technology is unique since there is no other magnetic
stirrer on the market that can both heat and cool and this versatility
is expected to be of great importance within research and laboratory
activities.The customers will be found among researchers in bio
and medical technology as well as in hospitals and universities.
The European market for the CoolHeater™ is estimated
to be more than 10 million US$.
|
Company name:
|
AB Implementa Hebe (priv)
|
|
Year of incorporation:
|
2000
|
|
Shares (total):
|
1 430 000
|
|
Shares (Institute):
|
490 000
|
LifeAssays
LifeAssaysTM was founded in the fall 2000
as a spin-off company from the European Institute of Science. The
Institute owns 100% of the company and is entitled to an annual
royalty of 2%.
Business idea
The business idea of LifeAssaysTM is to develop,
market and sell the patented Magneto ImmunoAssay ReaderTM and
disposable reagent vials for fast and easy determination of cancer
markers, acute phase proteins and hormones found in blood samples.
Technology and Patents
The operational principle is based on the use of extremely
small magnetically susceptible particles that are covered with antibodies,
enabling the particles to interact specifically with cancer markers,
acute phase proteins and hormones in blood. A prototype for fast
and accurate determination has been developed.
A patent has been granted in the US.
Market
Initially, LifeAssaysTM will focus on the
development of a reagent for the point-of-care market. Point-of-care
diagnostics is the fastest growing segment within the in vitro diagnostic
markets representing a 1 billion US$ market with 11% annual growth.
Our long-term strategy is to establish the Magneto ImmunoAssay Technology
on the word immunoassay market. The worldwide sales potential for
the Magneto ImmunoAssay reagents is in the range 100 - 500 million
US$.
|
Company name:
|
Lifeassays AB (publ)
|
|
Year of incorporation:
|
2000
|
|
Shares (total):
|
10 000 000
|
|
Shares (Institute):
|
10 000 000
|
|
